| __timestamp | BeiGene, Ltd. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21862000 | 461543000 |
| Thursday, January 1, 2015 | 58250000000 | 634806000 |
| Friday, January 1, 2016 | 98033000 | 661905000 |
| Sunday, January 1, 2017 | 269018000 | 610753000 |
| Monday, January 1, 2018 | 679005000 | 696328000 |
| Tuesday, January 1, 2019 | 927338000 | 715007000 |
| Wednesday, January 1, 2020 | 1294877000 | 628116000 |
| Friday, January 1, 2021 | 1459239000 | 628793000 |
| Saturday, January 1, 2022 | 1640508000 | 649606000 |
| Sunday, January 1, 2023 | 1778594000 | 746773000 |
| Monday, January 1, 2024 | 747184000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, BeiGene, Ltd. and BioMarin Pharmaceutical Inc. have demonstrated contrasting trajectories in their R&D investments. Since 2014, BeiGene has shown a remarkable increase in its R&D budget, growing by approximately 8,000% by 2023. This surge underscores BeiGene's aggressive pursuit of new therapies and market expansion. In contrast, BioMarin's R&D spending has remained relatively stable, with a modest increase of around 60% over the same period. This stability reflects BioMarin's focus on refining its existing portfolio and maintaining its niche in the rare disease sector. The data highlights the strategic differences between these two biotech leaders, offering insights into their future directions and potential market impacts.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and BeiGene, Ltd.
Who Prioritizes Innovation? R&D Spending Compared for Sanofi and BioMarin Pharmaceutical Inc.
BeiGene, Ltd. vs Incyte Corporation: Strategic Focus on R&D Spending
R&D Spending Showdown: BeiGene, Ltd. vs MorphoSys AG
R&D Insights: How BeiGene, Ltd. and MannKind Corporation Allocate Funds
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amneal Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
Comparing Innovation Spending: BioMarin Pharmaceutical Inc. and Soleno Therapeutics, Inc.
Research and Development Investment: BioMarin Pharmaceutical Inc. vs Dynavax Technologies Corporation
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Galapagos NV